India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drugmakers.
Deal’s fate rests on ‘talks about talks’ between senior officials as EU demands greater flexibility on imports.
As reported in Indian media, senior officials from the European Commission and India are expected to meet today in Brussels to hold talks on resuming negotiations on the proposed European Union-India free trade agreement.
Months after it called off talks between chief negotiators of the two sides on free trade agreement (FTA) to protest against the ban on sale of around 700 pharma products of a domestic company, India will meet officials from the European Union (EU) later next month to “take stock of the negotiations” on the long-pending FTA.
Implications of the TPP on the Indian pharma industry might not be entirely clear yet. But there is a need for India to engage in the debate of trade deals and public interest.
So far, the NDA government has been a mute spectator to the US pharma strategy of forcing Indian generics manufacturers to produce only what is required for Indian consumers and abandon the export of cheap drugs to Africa
The United States International Trade Commission (USITC) has published a report on IPR policy transparency by India’s new government
Ahead of a meeting between Indian Prime Minister Modi and German Chancellor Merkel this week, European manufacturers had already protested India’s patents policy, arguing that it doesn’t protect sensitive technology.
Médecins Sans Frontières/Doctors Without Borders (MSF) warned that US pressure for India to change its intellectual property policies could result in millions of people around the world losing their lifeline of affordable medicines.
The top members of US Congress and the Senate responsible for international trade issues urged the Obama administration to push for changes to India’s handling of intellectual property rights and technology
Less well known than the notorious Trans-Pacific Partnership, the Regional Comprehensive Economic Partnership (RCEP) is engendering growing opposition because of its similar oppressive provisions.
The EU and India are taking steps to end a trade row sparked by an EU ban of 700 Indian pharmaceutical products after New Delhi cancelled talks on a free trade accord earlier this month.
A big supplier of cheap lifesaving drugs to developing nations, India admirably balances public health needs with private profits and innovation. But it is under pressure to change this model.
Objecting to the ban of around 700 pharma products by the European Union, India said that it has called off a scheduled meeting of chief negotiators of the two sides on the proposed free trade agreement
Recently leaked documents show that India’s policies on software and pharmaceutical patents are firmly on the RCEP agenda.
As the eighth round of negotiations on the Regional Comprehensive Economic Partnership (RCEP) trade agreement take place in Kyoto, Japan this week, farmer’s groups, trade unions, civil society and patient groups are urging the Indian Government to halt the negotiations, make the negotiating texts public and hold consultations with all the relevant stakeholders, in light of the potential negative impact this agreement could have on access to medicines, livelihood of farmers, quality public services and overall social and economic development of the country.
Prof Brook K Baker, Professor of Law and Northeastern University, cautions that the Modi government’s accelerating flirtation with the US and its investors is dangerous to hundreds of millions of people worldwide whose lives depend on Indian generics
Japan is pushing for intellectual property rules in the Regional Comprehensive Economic Partnership that will undermine and delay access to affordable generic medecine in Asia.
The inclusion of intellectual property in the ongoing negotiations of the Regional Comprehensive Economic Partnership between 16 countries, most of them Asian, is raising concerns about “TRIPS-plus” measures that could jeopardise generic drugs production in India, according to Médecins Sans Frontières.
Le conseiller fédéral suisse Johann Schneider-Ammann a laissé entendre samedi dans la presse alémanique que la question de la protection des brevets pourrait retarder l’accord de libre-échange avec l’Inde.